title: The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study.
abstract: BACKGROUND
  Venous thromboembolism (VT) increases mortality and morbidity in cancer patients. The primary aim of this study was to evaluate the effect of VT on the survival of cancer patients and its relationship with serum vascular endothelial growth factor (VEGF) and plasma factor VIII levels.
  
  
  METHODS
  Eighty-two patients with locally advanced or metastatic cancer were included in this study between September 2001 and March 2004, and 31 of them had VT. Fifty-one matched-paired cancer patients without VT were prospectively selected as a control group in the same period. Criteria for the selection of control group patients were having the same malignancy, stage, metastatic site, performance status and age (+/-5 years) as patients in the VT group.
  
  
  RESULTS
  Plasma factor VIII and serum D-dimer levels in the VT group were significantly higher than those in the control group (p=0.030 and p=0.016, respectively). However, mean serum VEGF levels were similar in both groups (p=0.199). In the VT group, the median survival of patients who had higher serum VEGF levels (>150 pg/mL) was significantly shorter than that of patients in the same group with lower serum VEGF levels (p=0.005). The median survival of the VT group was 14 months, whereas it was 25 months in the control group (p=0.199).
  
  
  CONCLUSIONS
  There was a worse prognostic trend for cancer patients with VT. Nevertheless, the difference in survival was not statistically significant between the groups. Plasma factor VIII and serum D-dimer levels might have prognostic value in cancer patients with VT. Cancer patients with VT and higher serum VEGF levels had a significantly poorer prognosis.
authors.affiliation: Department of Medical Oncology, Ankara University School of Medicine, Cebeci Hospital, Dikimevi, Ankara, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Dogan
authors.forename: A
authors.initials: A
authors.lastname: Demirkazik
authors.forename: N
authors.initials: N
authors.lastname: Konuk
authors.forename: B
authors.initials: B
authors.lastname: Yalcin
authors.forename: A
authors.initials: A
authors.lastname: Buyukcelik
authors.forename: G
authors.initials: G
authors.lastname: Utkan
authors.forename: I
authors.initials: I
authors.lastname: Tek
authors.forename: H
authors.initials: H
authors.lastname: Akbulut
authors.forename: O
authors.initials: O
authors.lastname: Sencan
authors.forename: F
authors.initials: F
authors.lastname: Icli
mesh_terms: D000328:Adult; D000368:Aged; D005169:Factor VIII / Q000032:analysis*; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000401:mortality*; D011446:Prospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D020246:Venous Thrombosis / Q000097:blood*
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D042461:Vascular Endothelial Growth Factor A; C036309:fibrin fragment D; D005169:Factor VIII